Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 901–1,000 of 1,019
Szymański, F. M., Mickiewicz, A., Dzida, G. J., Gorczyca-Głowacka, I., Kozłowski, D., Widecka, K., Krasiński, Z., Kobayashi, A., Hering, D., Mizia‐Stec, K., et al. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0147 · Cited by 22
Psychiatric disorders associated with PCSK9 inhibitors: A real‐world, pharmacovigilance study
Deng, Z., Liu, J., Gong, H., Cai, X., Han, X., & Gao, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14522 · Cited by 21
Optimizing Treatment of Familial Hypercholesterolemia in Children and Adolescents
Luirink, I. K., Hutten, B. A., & Wiegman, A. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0629-1 · Cited by 22
Shin, J., Cho, K. H., Choi, Y. S., Lee, S. G., Park, E., & Jang, S. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.12.007 · Cited by 21
Ohshiro, T., Ohtawa, M., Nagamitsu, T., Matsuda, D., Yagyu, H., Davis, M. A., Rudel, L. L., Ishibashi, S., & Tomoda, H. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227348 · Cited by 21
The Role of a Coronary Artery Calcium Scan in Type 1 Diabetes
Burge, M. R., Eaton, R. P., & Schade, D. S. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0110 · Cited by 22
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Dufour, R., Bergeron, J., Gaudet, D., Weiss, R., Hovingh, G. K., Qing, Z., Yang, F., Andisik, M. D., Torri, A., Pordy, R. C., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.046 · Cited by 24
Self-citationPCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Preiss, D., & Mafham, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4178-y · Cited by 23
“While preliminary data from smaller, shorter trials have suggested substantial cardiovascular benefit (as much as a halving of major cardiovascular events) [35, 36], these results are based on only around 130 cardiovascular events, indicating that they should be interpreted with caution.”
BackgroundGanjali, S., Momtazi‐Borojeni, A. A., Banach, M., Kovanen, P. T., Gotto, A. M., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.014 · Cited by 22
Shi, Q., Liu, S., Krousel-Wood, M. A., Shao, H., Fonseca, V. A., & Shi, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.013 · Cited by 21
Ganda, O. P., Plutzky, J., Sanganalmath, S. K., Bujas‐Bobanovic, M., Koren, A., Mandel, J., Letierce, A., & Leiter, L. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13384 · Cited by 21
Petroglou, D., Kanellos, I., Savopoulos, C. G., Kaiafa, G. D., Chrysochoou, A., Skantzis, P., Daios, S., Hatzitolios, A. I., & Giannoglou, G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180604114819 · Cited by 23
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
“alirocumab out to 78 weeks, and favorable longer term outcome data was recently presented [31].”
BackgroundRobinson, J. G., & Davidson, M. H. (2018) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm19s1s0003 · Cited by 22
Self-citationEffect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Li, T., Yingyi, Z., & Cong, H. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01827-0 · Cited by 22
Xu, M., Lei, G., Chen, M., Wang, K., Lv, W., Zhang, P., Hu, T., Gao, J., Lü, C., Mei, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2021.103250 · Cited by 21
NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification
Oldham, W. M., Hemnes, A. R., Aldred, M. A., Barnard, J., Brittain, E. L., Chan, S. Y., Cheng, F., Cho, M. H., Desai, A. A., Garcia, J. G. N., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.056 · Cited by 22
Raccah, B. H., Yanovsky, A., Treves, N., Rotshild, V., Renoux, C., Danenberg, H. D., Eliaz, R., & Matok, I. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.025 · Cited by 23
Krittanawong, C., Khawaja, M., Rosenson, R. S., Amos, C. I., Nambi, V., Lavie, C. J., & Virani, S. S. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101043 · Cited by 21
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry
Cordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Rondán, J., Sandín, M., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13863 · Cited by 22
“remnants, (2) triglycerides/HDLc ratio (TG/HDL), (3) total cholesterol/HDLc”
MethodZhao, Y., Delaney, J. A., Quek, R. G. W., Gardin, J. M., Hirsch, C. H., Gandra, S. R., & Wong, N. D. (2016) · Clinical Cardiology · doi:10.1002/clc.22546 · Cited by 24
Lowering LDL Cholesterol Is Good, but How and in Whom?
Stone, N. J., & Lloyd‐Jones, D. M. (2015) · New England Journal of Medicine · doi:10.1056/nejme1502192 · Cited by 22
LDL-Cholesterol: Standards of Treatment 2016: A German Perspective
März, W., Scharnagl, H., Gouni‐Berthold, I., Silbernagel, G., Dressel, A., Grammer, T. B., Landmesser, U., Dieplinger, H., Windler, E., & Laufs, U. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0179-y · Cited by 22
“There was a statistically non-significant trend for more neurocognitive side effects in those using monoclonal antibodies against PCSK9 than in those receiving standard therapy [81, 82].”
BackgroundLDL cholesterol: How low to go?
Packard, C. J. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.011 · Cited by 21
Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis
Peters, L. J. F., Jans, A., Bartneck, M., & van der Vorst, E. P. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143185 · Cited by 20
Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery
Krebs, K., & Milani, L. A. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051421-111324 · Cited by 20
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?
Liu, K., Cooper, M. E., Chai, Z., & Liu, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041683 · Cited by 20
“Statins, ezetimibe, and PCSK9 inhibitors can slightly increase the plasma levels of HDL-C, but their cardiovascular and renal benefits are only causally related to their ability to primarily lower LDL-C [196,198–200].”
New and Emerging Biomarkers in Cardiovascular Disease
Cahill, L. E., Bertoia, M. L., Aroner, S. A., Mukamal, K. J., & Jensen, M. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0661-y · Cited by 21
Cannon, C. P., Sanchez, R. J., Klimchak, A. C., Khan, I., Sasiela, W. J., Reynolds, M. R., & Rosenson, R. S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.01.028 · Cited by 21
Ntaios, G., & Milionis, H. J. (2019) · International Journal of Stroke · doi:10.1177/1747493019851283 · Cited by 23
“9%) in the alirocumab group compared to the placebo group.(14)”
ResultLowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1246-y · Cited by 24
Hwang, J., Choi, E., Choi, H., Park, J., & Chung, M. (2021) · Foods · doi:10.3390/foods10020408 · Cited by 21
Mooradian, A. D. (2016) · Drugs · doi:10.1007/s40265-016-0609-9 · Cited by 22
“However, lowering of low density lipoprotein (LDL) cholesterol with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may also prove to be clinically effective in reducing cardiovascular events [117, 118] and recently ezetimibe, a cholesterol absorption inhibitor, was also shown for the first time to ha…”
BackgroundBea, A. M., Pérez‐Calahorra, S., Marco-Benedí, V., Lamíquiz-Moneo, I., Jarauta, E., Mateo‐Gállego, R., & Civeira, F. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.009 · Cited by 20
Langlois, M. R., & Nordestgaard, B. G. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1036-1 · Cited by 19
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies
Catapano, A. L., Mikhailova, E., Navar, A. M., Banka, P., Corral, P., Saxena, M., Steg, P. G., Verma, S., Kordahi, A. Y., Mendizabal, G., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.036 · Cited by 19
Evolocumab: A Review in Hyperlipidemia
Keating, G. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0153-0 · Cited by 19
“3 % of patients receiving standard therapy alone in the OSLER-1 and -2 analysis [33].”
BackgroundMethodInfluentialHow Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?
Zimmerman, M. P. (2015) · Europe PMC (PubMed Central) · Cited by 21
Glueck, C. J., Shah, P. K., Goldenberg, N., Prince, M., Lee, K., Jetty, V., Kumar, A., Goldenberg, M., & Wang, P. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0227-2 · Cited by 20
“On Alirocumab, injection site reactions, myalgia, neurocognitive events, and ophthalmologic events were more common than on placebo [1].”
BackgroundMethodInfluentialFahy, E. F., McCarthy, E. K., Steinhagen‐Thiessen, E., & Vaughan, C. J. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.10.002 · Cited by 19
Advanced Research of Abdominal Aortic Aneurysms on Metabolism
Hou, Y., Guo, W., Fan, T., Li, B., Ge, W., Gao, R., & Wang, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.630269 · Cited by 19
“Evolocumab and Alirocumab, as PCSK9 inhibitors, have been approved for the clinical treatment of hyperlipidemia in many countries and regions (108, 109), but their actual effects on AAA have not been tested in clinical studies.”
BackgroundWang, H., Mao, Y.-C., Xu, X., Zhao, S., Han, D.-D., Ge, S., Song, K., Geng, C., & Tian, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1016802 · Cited by 20
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
Alannan, M., Seidah, N. G., & Merched, A. J. (2022) · Cells · doi:10.3390/cells11244132 · Cited by 22
“Alirocumab (Praluent) mAb FDA-approved for treating hypercholesterolemia +/− Statins [119,122,123]”
BackgroundMethodWang, X., Qiu, M., Cheng, Z., Ji, X., Chen, J., Hong, Z., Tang, Y., Huang, Z., Su, G., Wang, G., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033669 · Cited by 19
“16 Moreover, ongericimab 150 mg every 2 weeks enabled 87.5% to 91.4% of patients at extremely high risk to achieve the LDL-C target of 1.4 mmol/L (55 mg/dL), and 88.1% to 91.8% of patients at very high risk to achieve the LDL-C target of 1.8 mmol/L (70 mg/dL).”
BackgroundInfluentialZahger, D., Schwartz, G. G., Du, W., Szarek, M. J., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Jukema, J. W., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.035 · Cited by 22
Self-citationOSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events
Hassan, M. S. (2015) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2015.20 · Cited by 23
Moriarty, P. M., Parhofer, K. G., Babirak, S. P., deGoma, E. M., Duell, P. B., Hohenstein, B., Ramlow, W., Simha, V., Steinhagen‐Thiessen, E., Thompson, P. D., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.003 · Cited by 19
Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies
Patel, R. S., Scopelliti, E. M., & Savelloni, J. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1672 · Cited by 19
“In the ODYSSEY LONG TERM trial, patients with HeFH, established CHD, or CHD risk equivalent and LDL of 70 mg/ dl or higher were randomized to receive alirocumab or placebo in addition to statin therapy.(65) A total of 2341 patients were enrolled in the trial, with a mean age of 60 years and a baseline LDL-C of 122 mg/…”
BackgroundMethodResultInfluentialHipercolesterolemia familiar: artículo de revisión
Merchán, A., Ruiz, Á. J., Campo, R., Prada, C. E., Toro, J. M., Sánchez, R., Gómez‐Mesa, J. E., Jaramillo, N. I., Molina, D. I., Vargas‐Uricoechea, H., et al. (2016) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.05.002 · Cited by 33
Lipoprotein(a): A Lipoprotein Whose Time Has Come
Kelly, E. M., & Hemphill, L. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0549-z · Cited by 20
Catapano, A. L., Pirillo, A., & Norata, G. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s130338 · Cited by 20
Trials and Frontiers in Carotid Endarterectomy and Stenting
Jones, D. W., Brott, T. G., & Schermerhorn, M. L. (2018) · Stroke · doi:10.1161/strokeaha.117.019496 · Cited by 19
Ravnskov, U., de Lorgeril, M., Kendrick, M. E., & Diamond, D. M. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.09.019 · Cited by 19
The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
Silbernagel, G., Steiner, L. K., Hollstein, T., Fauler, G., Scharnagl, H., Stojaković, T., Schumann, F., Bölükbasi, B., März, W., Steinhagen‐Thiessen, E., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p088583 · Cited by 19
Dufour, R., Hovingh, G. K., Guyton, J. R., Langslet, G., Baccara‐Dinet, M. T., Din-Bell, C., Manvelian, G. Z., & Farnier, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.11.007 · Cited by 20
Self-citationDijk, W., & Cariou, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13636 · Cited by 19
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
“ODYSSEY LONG TERM (Robinson et al., 2015) 2015 PCSK/ST vs.”
BackgroundLi, H., Li, J., Zhang, X., Li, J., Xi, C., Wang, W.-Q., Lu, Y., & Xuan, L. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0274-0 · Cited by 19
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations
Heine, G. H., Eller, K., Stadler, J. T., Rogacev, K. S., & Marsche, G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107459 · Cited by 20
Schwartz, G. G., & Giugliano, R. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000830 · Cited by 19
Alirocumab: First Global Approval
Markham, A. (2015) · Drugs · doi:10.1007/s40265-015-0469-8 · Cited by 19
“The reduction in LDL-C levels was consistent from week 4 to week 78 in alirocumab recipients [12].”
BackgroundAlirocumab: A Review in Hypercholesterolemia
Greig, S. L., & Deeks, E. D. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0166-3 · Cited by 20
“Where reported [14, 19–23, 25, 26], ontreatment analyses were conducted in the modified ITT population.”
BackgroundMethodInfluentialClinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
Ling, H., Henry, C., & Ra, L. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s82387 · Cited by 20
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Elamin, A., Grafton‐Clarke, C., Chen, K. W., Obafemi, T., Luvai, A., Katira, R., & Davis, G. K. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136171 · Cited by 19
PCSK9 monoclonal antibodies: An overview
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Heart Views · doi:10.4103/heartviews.heartviews_20_20 · Cited by 20
“, Vitamin E or K) and steroid hormones in the studies that measured their levels as part of a prespecified safety analysis.[55,71]”
BackgroundMethodInfluentialSakamoto, A., Cornelissen, A., Sato, Y., Mori, M., Kawakami, R., Kawai, K., Ghosh, S. K. B., Xu, W., Abebe, B., Dikongue, A., et al. (2022) · US Cardiology Review · doi:10.15420/usc.2021.22 · Cited by 22
New Biological Therapies for Low-Density Lipoprotein Cholesterol
Gill, P. K., & Hegele, R. A. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.003 · Cited by 19
Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 19
Cancer and Cardiovascular Disease: The Conjoined Twins
Zmaili, M. A., Alzubi, J. M., Alkhayyat, M. M., Albakri, A. A., Alkhalaileh, F., Longinow, J., & Moudgil, R. (2024) · Cancers · doi:10.3390/cancers16081450 · Cited by 21
Aguchem, R. N., Okagu, I. U., Okorigwe, E. M., Uzoechina, J. O., Nnemolisa, S. C., & Ezeorba, T. P. C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122823 · Cited by 18
PCSK9 in T-cell function and the immune response
Wang, Y., Fang, X., Liu, J., Lv, X., Lu, K., Lu, Y., & Jiang, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00712-8 · Cited by 19
“According to a post hoc analysis of one trial, the rate of major adverse cardiovascular events (coronary heart disease-related death, myocardial infarction, unstable angina requiring hospitalization, or ischemic stroke) was lower in the alirocumab group than in the placebo group ( p = 0.02) [32].”
InfluentialMiyoshi, T., Nakamura, K., Doi, M., & Ito, H. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0119-2 · Cited by 18
Advances in the treatment of dyslipidemia
Sabatine, M. S. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83gr.16001 · Cited by 18
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 19
Wong, N. D., Rosenblit, P. D., & Greenfield, R. S. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.03.02 · Cited by 20
Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice
Sinning, D., & Landmesser, U. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317708349 · Cited by 20
“A profound and persistent reduction of LDL cholesterol levels by up to approximately 60% was confirmed by numerous studies with different monoclonal antibodies against PCSK9.(11,12,37,38) Alirocumab and evolocumab are two PCSK9 antibodies already approved and in clinical use in Europe.”
BackgroundResultLappegård, K. T., Kjellmo, C. A., Ljunggren, S., Cederbrant, K., Marcusson‐Ståhl, M., Mathisen, M. D., Karlsson, H., & Hovland, A. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.01.002 · Cited by 19
Weisshaar, S., & Zeitlinger, M. A. (2018) · Drugs · doi:10.1007/s40265-018-0915-5 · Cited by 18
Gao, Y., Qiu, Y., Wu, J., Diao, W., Zhang, H., Wang, S., Du, Z., Dong, J., Zhang, M., & Jiang, L. (2018) · Cardiology · doi:10.1159/000493785 · Cited by 19
Petrov, I. S., Dumitrescu, A., Šnejdrlová, M., Zafrir, B., Wożakowska−Kapłon, B., Fábryová, Ľ., Pintarić, H., Bridges, I. M., & Petkova, R. T. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0879-1 · Cited by 19
Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake
Galvan, A. M., & Chorba, J. S. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m087189 · Cited by 19
Guarnieri, F., Kulp, J. L., Kulp, J. L., & Cloudsdale, I. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225780 · Cited by 19
Amput, P., Palee, S., Arunsak, B., Pratchayasakul, W., Thonusin, C., Kerdphoo, S., Jaiwongkam, T., Chattipakorn, S. C., & Chattipakorn, N. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15556 · Cited by 18
Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions
Yanaka, K., Akahori, H., Imanaka, T., Miki, K., Yoshihara, N., Kimura, T., Tanaka, T., Asakura, M., & Ishihara, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.56457 · Cited by 19
Zhou, E., Li, Z., Nakashima, H., Choukoud, A., Kooijman, S., Berbée, J. F. P., Rensen, P. C. N., & Wang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105524 · Cited by 19
Ma, W., Guo, X., Ma, Y., & Hu, Z. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.008 · Cited by 18
McKay, A. J., Gunn, L. H., Ference, B. A., Dorresteijn, J. A. N., Berkelmans, G. F. N., Visseren, F. L. J., & Ray, K. K. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab093 · Cited by 19
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
Gaudet, D., Ruzza, A., Bridges, I. M., Maruff, P. T., Schembri, A. J., Hamer, A. W., Mach, F., Bergeron, J., Gaudet, I., St‐Pierre, J., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.005 · Cited by 18
Self-citationZhou, Z., Zhang, W., Burgner, D. P., Tonkin, A. M., Zhu, C., Sun, C., Magnussen, C. G., Ernst, M. E., Breslin, M. C., Nicholls, S. J., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.02.025 · Cited by 18
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
Marian, A. J. (2016) · Circulation Research · doi:10.1161/circresaha.116.308830 · Cited by 18
Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance
Vassiliou, V. S., Flynn, P. D., Raphael, C. E., Newsome, S., Khan, T. Z., Ali, A., Halliday, B. P., Bruengger, A. A. S., Malley, T. S., Sharma, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181077 · Cited by 18
de Armas‐Rillo, L., Quevedo-Abeledo, J. C., de Vera-González, A., Delgado, A. G., García-Dopico, J. A., Jiménez, A., Rodríguez‐Lozano, C., González-Gay, M. Á., & Ferraz‐Amaro, I. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa590 · Cited by 18
PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
Cainzos‐Achirica, M., Martin, S. S., Cornell, J. E., Mulrow, C. D., & Güallar, E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0920 · Cited by 18
Sabatine, M. S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw572 · Cited by 19
Long-term levels of LDL-C and cognitive function: the CARDIA study
Mefford, M. T., Chen, L., Lewis, C. E., Muntner, P., Sidney, S., Launer, L. J., Monda, K. L., Ruzza, A., Kassahun, H., Rosenson, R. S., et al. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721000059 · Cited by 15
“Given potential associations with LDL-C and cognition, we also examined potential effect modification by statin use ("FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs," 2012; Stroes, 2005), PCSK9 loss-of-function (LOF) variants (Robinson et al., 2015; Sabatine et al.,…”
BackgroundKasliwal, R. R., Bansal, M., Gupta, R., Shah, S., Dani, S., Oomman, A., Pai, V., Prasad, G. M., Singhvi, S., Patel, J., et al. (2016) · Nutrition · doi:10.1016/j.nut.2016.01.012 · Cited by 17
Su, C.-Y., van der Graaf, A., Zhang, W., Jang, D.-K., Selber-Hnatiw, S., Yang, T.-Y., Butler-Laporte, G., Liang, K. Y. H., Matsuda, F., Costanzo, M. C., et al. (2024) · doi:10.1101/2024.10.17.24315553 · Cited by 17
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.